X

Trial Profile

Observational Cohort Trial-T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Acronyms OCTAVE

Most Recent Events

02 Aug 2022 The total final enrolment was changed from 2669 to 2812.
02 Aug 2022 The overall trial end date was changed from 31/07/2022 to 31/10/2024.
26 Jun 2022 Results investigating humoral and cellular immune responses in patients across Europe with cirrhosis, autoimmune hepatitis (AIH), liver transplantation (LT), and vascular liver disorders, presented at The International Liver Congress 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com